The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SEPN | -17.1% | N/A | N/A | -10% |
| S&P | +12.57% | +87.93% | +13.44% | +16% |
Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by proprietary Native Complex PlatformTM. Its pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. The company was founded by Robert Joseph Lefkowitz, Arthur Christopoulos, Patrick Sexton, and Jeffrey T. Finer in December 2019 and is headquartered in South San Francisco, CA.
No news articles found for Septerna.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $21.50M | 12113.1% |
| Gross Profit | $21.10M | 11320.7% |
| Gross Margin | 98.14% | 205.0% |
| Market Cap | $838.65M | 0.0% |
| Market Cap / Employee | $11.18M | 0.0% |
| Employees | 75 | 0.0% |
| Net Income | $8.17M | 139.8% |
| EBITDA | -$9.49M | 57.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $319.99M | 262.6% |
| Accounts Receivable | $8.65M | 4016.7% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $21.99M | -8.8% |
| Short Term Debt | $2.12M | 89.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -15.06% | 0.0% |
| Return On Invested Capital | -35.49% | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $168.79M | 1070.5% |
| Operating Free Cash Flow | $168.81M | 1104.0% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -11.63 | 0.61 | 1.17 | 2.22 | - |
| Price to Sales | 689.84 | 260.39 | 643.01 | 38.91 | - |
| Price to Tangible Book Value | -11.63 | 0.61 | 1.17 | 2.22 | - |
| Price to Free Cash Flow TTM | 8.32 | - | |||
| Enterprise Value to EBITDA | -17.10 | 2.22 | -5.77 | -42.96 | - |
| Free Cash Flow Yield | 12.0% | - | |||
| Return on Equity | -27.0% | -32.8% | -22.4% | - | |
| Total Debt | $25.48M | $25.03M | $24.57M | $24.11M | -4.42% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
